Short answer
AVITA Medical, Inc. (RCEL) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Cary Vance appointed CEO effective April 30, 2026, transitioning from Interim CEO and Executive Chairman.
AVITA Medical, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Cary Vance appointed CEO effective April 30, 2026, transitioning from Interim CEO and Executive Chairman
- Jan Stern Reed appointed Board Chair, replacing the Lead Independent Director structure
- Employment agreement includes $702,000 annual salary and three-year initial term
- Equity awards total $3.354 million, subject to stockholder approval at the 2027 annual meeting
- Annual bonus target equals 80% of base salary; termination benefits include 18 months’ salary and COBRA reimbursement
Item 7.01 · Regulation FD Disclosure
- CEO appointments of Mr. Vance and Ms. Reed disclosed under Regulation FD
- Leadership changes may affect strategy, execution priorities, and investor confidence
- Full appointment details and effective dates provided in the referenced press release
Item EX-99.1 · Exhibit EX-99.1
- Cary Vance appointed permanent President and CEO, effective immediately, following interim tenure since October 2025
- Jan Stern Reed appointed independent Board Chair, replacing her Lead Independent Director role held since October 2025
- Leadership continuity may support strategic execution, adoption of RECELL, and investor confidence
- First-quarter 2026 earnings call scheduled for May 14, 2026 at 1:30 p.m. Pacific Time
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVITA Medical, Inc. 8-K filings
Get the next RCEL 8-K as it lands
Follow RCEL for push alerts, or ask the research agent what this filing means.